Evaluating Brexpiprazole for the Management of Behavioral and Psychological Symptoms of Dementia
In this CME article, learn more about the efficacy and tolerability of brexpiprazole for the treatment of agitation among individuals with Alzheimer disease dementia.
The Safety of Psychostimulants or Atomoxetine for Patients With Psychotic Disorders
Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.
Treatment Options for the Management of Behavioral and Psychological Symptoms of Dementia
The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.
Zuranolone for the Treatment of Adults With Major Depressive Disorder
This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.
Treatment-Resistant Geriatric Depression: Augmenting or Switching an Antidepressant
Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.
Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Efficacy Studies of Semaglutide for Type 2 Diabetes Mellitus
February 13th 2024One meta-analysis that included data from 6 placebo-controlled and 7 active-controlled studies using subcutaneous semaglutide found that when compared with placebo, subcutaneous semaglutide 0.5 mg and 1 mg reduced hemoglobin A1c (HbA1c) by 1.01% and 1.38%, respectively.
Different Strokes: How to Spot and Treat Poststroke Depression
May 20th 2021Available evidence indicates that there are a multitude of neuropsychiatric syndromes that occur after a stroke. Cognitive impairment occurs in approximately one-third of patients. These neuropsychiatric manifestations often impede the recovery of motor functioning, reduce social functioning, and decrease the overall quality of life.